|Articles|December 6, 2010

Resistance Does Not Greatly Impact Mortality in ICU Patients with HAIs

Antibiotic resistance is a complication of treating patients in the intensive care unit (ICU) who have contracted healthcare-acquired infections (HAIs), but according to Marie-Laurence Lambert, MD, of the of the Scientific Institute of Public Health in Brussels, and colleagues, this resistance does not increase mortality. The research was published online in Lancet Infectious Diseases.

In their study, Lambert, et al. (2010) sought to assess excess mortality and length of stay in intensive-care units from bloodstream infections and pneumonia. The researchers analysed data collected prospectively from ICUs that reported according to the European standard protocol for surveillance of HAIs, focusing on the most frequent causative microorganisms. Resistance was defined as resistance to ceftazidime (Acinetobacter baumannii or Pseudomonas aeruginosa), third-generation cephalosporins (Escherichia coli), and oxacillin (Staphylococcus aureus). The researchers defined 20 different exposures according to infection site, microorganism and resistance status. For every exposure, the researchers compared outcomes between patients exposed and unexposed by use of time-dependent regression modelling, and adjusted results for patients' characteristics and time-dependency of the exposure.

The researchers report that they obtained data for 119,699 patients who were admitted for more than two days to 537 ICUs in 10 countries between Jan 1, 2005, and Dec 31, 2008. Excess risk of death (hazard ratio) for pneumonia in the fully adjusted model ranged from 1·7 (95% CI 1·41·9) for drug-sensitive S aureus to 3·5 (2·94·2) for drug-resistant P aeruginosa. For bloodstream infections, the excess risk ranged from 2·1 (1·62·6) for drug-sensitive S aureus to 4·0 (2·75·8) for drug-resistant P aeruginosa. Risk of death associated with antimicrobial resistance (ie, additional risk of death to that of the infection) was 1·2 (1·11·4) for pneumonia and 1·2 (0·91·5) for bloodstream infections for a combination of all four microorganisms, and was highest for S aureus (pneumonia 1·3 [1·01·6], bloodstream infections 1·6 [1·12·3]). Antimicrobial resistance did not significantly increase length of stay; the hazard ratio for discharge, dead or alive, for sensitive microorganisms compared with resistant microorganisms (all four combined) was 1·05 (0·971·13) for pneumonia and 1·02 (0·981·17) for bloodstream infections. P aeruginosa had the highest burden of HAIs because of its high prevalence and pathogenicity of both its drug-sensitive and drug-resistant strains.

The researchers conclude that healthcare-acquired bloodstream infections and pneumonia greatly increase mortality and pneumonia increases length of stay in intensive-care units, but that the additional effect of the most common antimicrobial resistance patterns is comparatively low.

Reference: Lambert ML, Suetens C, Savey A, Palomar M, Hiesmayr M, Morales I, Agodi A, Frank U, Mertens K, Schumacher M and Wolkewitz M. Clinical outcomes of health-care-associated infections and antimicrobial resistance in patients admitted to European intensive-care units: a cohort study. The Lancet Infectious Diseases. Dec. 1, 2010.


Related to this article

Water  (Adobe Stock 456102510 by stockphoto-graf)
Understanding current water quality is a starting point for ST108 implementation. John Kimsey, vice president of processing optimization and customer success for STERIS, spoke about his HSPA presentation on assessing readiness, distinguishing system qualification from routine testing, and understanding where water samples should be collected.
Image of Pathogens flying   (Adobe Stock weerasak)
Behind every landmark in infection prevention, from antimicrobial stewardship guidelines to the COVID-19 town halls that reached flight attendants and teachers, is a generation of physician-scientists who led SHEA through crises, organizational change, and scientific breakthroughs. Infection Control Today traces 30 years of SHEA presidents and the lasting mark they left on the field.
AORN26 New Orleans 2026  (Adobe Stock)
Missing instruments and processing delays can strain OR–SPD relationships. At AORN 2026, John Kimsey, vice president of processing optimization and customer success for STERIS, discusses understanding root causes, exploring off-site reprocessing for ambulatory surgical centers, and using hands-on simulation to help surgical teams see sterile processing from a different perspective.